HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Multidrug resistant tuberculosis — Clinical Guidelines

Overview

Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis caused by bacteria resistant to at least isoniazid and rifampin, posing significant therapeutic and public health challenges 1 4.

Diagnosis

Laboratory confirmation through culture and drug susceptibility testing 1.

Clinical symptoms include persistent cough, fever, weight loss, and night sweats 1.

No specific grading system universally accepted; diagnosis relies heavily on microbiological evidence 1.

Management

First-line treatments: Second-line drugs such as fluoroquinolones (e.g., moxifloxacin), injectable agents (e.g., amikacin, kanamycin), and bedaquiline 1 8.

Adjunctive treatments: Supportive care including nutritional support, management of adverse drug reactions, and addressing comorbidities 9.

Targeted interventions: Use of marginal structural models to personalize treatment based on patient characteristics and co-medications 4.

Special Populations

Pregnancy: Limited evidence suggests higher rates of adverse birth outcomes including maternal death, pregnancy loss, preterm birth, and low birthweight 5.

Adverse reactions: Frequent in all populations, particularly impacting adherence and outcomes when compounded with non-adherence 9.

Key Recommendations

Implement systematic reviews and meta-analyses using mixed aggregate and individual participant data for robust treatment effectiveness estimates (Evidence: Moderate) 1.

Consider moxifloxacin as a prophylaxis option for contacts of MDR-TB patients, monitoring for efficacy and tolerability (Evidence: Weak) 8.

Address adverse drug reactions proactively to improve adherence and treatment outcomes, especially in adherent patients (Evidence: Moderate) 9.

Develop and implement standardized protocols for managing MDR-TB in specialized units to enhance control and reduce economic burden (Evidence: Expert opinion) 7.

Provide targeted decolonization and perioperative antibiotic prophylaxis strategies for MDR-Gram-positive bacteria carriers undergoing surgery, focusing on reducing surgical site infections (Evidence: Moderate) 2.

References

1 Siddique AA, Schnitzer ME, Balakrishnan N, Sotgiu G, Vargas MH, Menzies D et al.. Two-stage targeted maximum likelihood estimation for mixed aggregate and individual participant data analysis with an application to multidrug resistant tuberculosis. Statistics in medicine 2024. link 2 Righi E, Mutters NT, Guirao X, Dolores Del Toro M, Eckmann C, Friedrich AW et al.. European Society of Clinical Microbiology and Infectious Diseases/European Committee on infection control clinical guidelines on pre-operative decolonization and targeted prophylaxis in patients colonized by multidrug-resistant Gram-positive bacteria before surgery. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2024. link 3 Baig S. MDR TB-The Lethal Sound of Silent Mutations. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2024. link 4 Liu Y, Schnitzer ME, Wang G, Kennedy E, Viiklepp P, Vargas MH et al.. Modeling treatment effect modification in multidrug-resistant tuberculosis in an individual patientdata meta-analysis. Statistical methods in medical research 2022. link 5 Alene KA, Jegnie A, Adane AA. Multidrug-resistant tuberculosis during pregnancy and adverse birth outcomes: a systematic review and meta-analysis. BJOG : an international journal of obstetrics and gynaecology 2021. link 6 Heckel M, Illig A, Brunner S, Ostgathe C. Evaluating the implementation of national recommendations on multidrug-resistant bacterial microorganisms in end-of-life care. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen 2020. link 7 Gagnaire J, Gagneux-Brunon A, Pouvaret A, Grattard F, Carricajo A, Favier H et al.. Carbapenemase-producing Acinetobacter baumannii: An outbreak report with special highlights on economic burden. Medecine et maladies infectieuses 2017. link 8 Trieu L, Proops DC, Ahuja SD. Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA. Emerging infectious diseases 2015. link 9 Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S et al.. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2007. link 10 Flego M, Mennella V, Moretti F, Poloni F, Dupuis ML, Ascione A et al.. Identification by phage display of the linear continuous MRPr1 epitope in the multidrug resistance-associated protein (MRP1). Biological chemistry 2003. link

Multidrug resistant tuberculosis